Literature DB >> 28446292

[Relation of MiR-34a Expression in Diffuse Large B Cell Lymphoma with Clinical Prognosis].

Yi-Ping Liu1, Hong Hu2, Fang Xu1, Jing-Jing Wen1.   

Abstract

OBJECTIVE: To investigate the expression of miR-34a in serum of DLBCL patients, and to analyze its correlation with the expression of BCL-2 protein and clinical prognosis.
METHODS: The clinical data of 65 DLBCL patients and 22 cases of lymphonode reactive hyperplasia (RH) were collected, the serum expressions of miR-34a and BCL-2 were detected by real-time fluorescence quantitative PCR, and the relationship of miR-34a and BCL-2 expression with clinical pathological features and prognosis was analyzed.
RESULTS: The miR-34a lowly expressed in DLBCL and the BCL-2 highly expressed in DLBCL, the miR-34a expression level correlated negatively with BCL-2 expression (P<0.01). The survival time of patients with high expression of miR-34a was significantly longer than that of patients with miR-34a low expression. Multivariate Cox regression analysis revealed that the expression of miR-34a (P<0.01) and BCL-2 (P<0.01) as well as clinical staging (P<0.01) were independent factors influencing the prognosis of patients with DLBCL.
CONCLUSION: The low expression of miR-34a in DLBCL patients may be involved in the occurrence and development of diffuse large B cell lymphoma, the MiR-34a is correlated with prognosis of diffuse large B cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28446292     DOI: 10.7534/j.issn.1009-2137.2017.02.026

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  2 in total

1.  MicroRNA‑34a inhibits liver cancer cell growth by reprogramming glucose metabolism.

Authors:  Hai-Feng Zhang; Yi-Cheng Wang; Yi-Di Han
Journal:  Mol Med Rep       Date:  2018-01-09       Impact factor: 2.952

Review 2.  The emerging role non-coding RNAs in B cell-related disorders.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Elena Jamali
Journal:  Cancer Cell Int       Date:  2022-02-22       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.